U.S./Israel-Iran War: the Middle East On Edge
NextFin News - BASF SE raised its full-year earnings outlook for the second time in 2026 on Wednesday, lifting its EBITDA before special items forecast to between €7.4 billion and €7.8 billion after third-quarter sales climbed 14 percent to €16.4 billion on the back of double-digit price increases. The move caps a year in which Europe's largest chemical producer has steadily upgraded its profit trajectory even as underlying sales volumes grew only modestly — a split that raises the question of how durable the earnings recovery really is.
The company now expects EBITDA before special items of €7.4 billion to €7.8 billion for the 2026 business year, up from the €6.9 billion to €7.7 billion range set in July and well above the €6.2 billion to €7.0 billion forecast it started the year with. Third-quarter earnings before interest, taxes, depreciation and amortization, excluding special items, rose 15 percent to €1.6 billion, with an EBITDA margin before special items of 10.0 percent, flat with the prior-year period.
What the Numbers Actually Say
The headline strength came from pricing, not demand. BASF said the 14 percent sales increase to €16.4 billion — €2 billion above the third quarter of 2025 — was driven mainly by considerably higher prices, up 12 percent, while volumes edged up just 2 percent. Positive currency effects, particularly from the U.S. dollar and the Chinese renminbi, also contributed. That pattern follows the first half of the year, when sales rose 6.2 percent to €33.2 billion on volume growth of 5.7 percent and price gains of 4.8 percent, with the second quarter alone seeing prices jump 11.5 percent.
Earnings before special items increased by €213 million to €1.6 billion, lifted by stronger results in the Chemicals, Nutrition & Care, Materials and Industrial Solutions segments, which more than offset declines in Agricultural Solutions and Surface Technologies. Prices improved considerably in Chemicals, Materials, Surface Technologies and Industrial Solutions, and slightly in Nutrition & Care, while Agricultural Solutions saw a slight price decline. Volumes rose substantially in Chemicals and Nutrition & Care but fell significantly in Agricultural Solutions.
Below the headline earnings line, the picture was rougher. EBIT came in at minus €98 million, compared with a positive €232 million in the prior-year quarter, after depreciation and amortization of €1.3 billion — including a €318 million impairment in the Monomers division. Special items totaled minus €437 million, stemming largely from transformation expenses for restructuring at the Ludwigshafen site and a settlement of a legal dispute in the Care Chemicals division. Net income slipped to €155 million from €172 million, and earnings per share fell to €0.18 from €0.19. On an adjusted basis, excluding special items and amortization of intangible assets, earnings per share rose to €0.72 from €0.52.
Cash generation remained solid despite higher raw-material costs. Free cash flow in the quarter was €523 million, up €125 million year over year, helped by €434 million in proceeds from the disposal of shares in Harbour Energy and lower payments for the Zhanjiang Verbund site in China. But operating cash flow of €1.1 billion was €275 million below the prior-year quarter, as €507 million of cash became tied up in inventories — predominantly because of higher raw-material prices — compared with €6 million released a year earlier.
"The strong year-to-date performance of our core businesses gives us confidence to narrow our forecast range for EBITDA before special items upward," said Dr. Markus Kamieth, Chairman of BASF's Board of Executive Directors, who presented the figures alongside Chief Financial Officer Dr. Dirk Elvermann.
The company kept its other 2026 targets unchanged: free cash flow of €1.5 billion to €2.3 billion and CO2 emissions of 17.2 million to 18.2 million metric tons. It also maintained its macroeconomic assumptions — global GDP growth of 2.5 percent, industrial production growth of 2.0 percent, chemical production growth of 1.8 percent, an average euro-dollar rate of $1.17, and Brent crude at $80 per barrel — while citing continuing uncertainty around geopolitical and global economic developments.
The Price Engine: How Much Is Real Growth?
The central fact of BASF's 2026 turnaround is that it is being led by price, not volume. Across the first nine months of the year, the company has repeatedly pointed to price effects as the dominant driver of sales growth, while volumes have been inconsistent — strong in the second quarter, muted in the third. That matters because price-led earnings are only as durable as the market's willingness to absorb them.
In the chemical industry, pricing power typically appears in two forms. The first is genuine demand strength: customers order more, inventories are low, and producers can raise prices without losing share. The second is cost pass-through: input prices rise — whether from energy, feedstock, or supply disruptions — and producers lift selling prices to protect margins. The third-quarter cash-flow statement suggests BASF is dealing with a mix weighted toward the second. The €507 million inventory build, driven by higher raw-material prices, is the signature of a company buying more expensive inputs and holding them on the balance sheet while it passes costs through to customers.
This distinction is not academic. If the price increases reflect pass-through, then the earnings lift is a margin-recovery story — welcome, but not a sign of structural demand growth. If they reflect genuine volume-led pricing power, they would signal a deeper cyclical upturn. The 2 percent volume increase in the third quarter, following 5.7 percent volume growth in the first half, points to the former: BASF is protecting margins in a market where real demand growth remains thin.
Cyclical Windfall or Structural Turnaround?
The tougher question for investors is whether BASF's rising guidance reflects a cyclical wave that will recede or a structural shift in the company's earning power. The evidence points to both forces operating at once — and that duality is what makes the stock's current valuation debate so contested.
On the cyclical side, a significant portion of 2026's earnings strength traces to indirect effects from the conflict in the Middle East, which disrupted supply chains and lifted prices and margins for chemical producers with intact capacity. Fitch Ratings, in affirming BASF's 'A' rating with a stable outlook on October 26, attributed its forecast of roughly €7 billion in EBITDA for 2026 in part to these "positive indirect effects from the conflict in the Middle East on both volumes and margins." The same agency, however, expects Fitch-defined EBITDA to decline about 2 percent in 2027 as volumes from the new Zhanjiang Verbund site only partly offset a return to bottom-of-cycle margins amid global chemical oversupply, high feedstock and energy costs, and rising competition.
On the structural side, BASF is in the middle of a multi-year transformation that is genuinely reshaping its cost base and portfolio. Restructuring at the Ludwigshafen site, the divestiture of the automotive coatings businesses to Carlyle — which closed on June 30 and generated €5.8 billion in pre-tax proceeds — and the ramp-up of the Zhanjiang site in China are not one-off events. They are designed to permanently lower the company's break-even point. The repeated special-item charges, including the €437 million in the third quarter, are the accounting signature of that restructuring, and they sit alongside steadily improving underlying earnings.
The verdict: the cyclical leg is carrying the near-term numbers, but the structural leg is what gives management the confidence to keep raising guidance. The risk is timing. If the Middle East-driven price effects unwind faster than the restructuring delivers cost savings, earnings could stall in 2027 before the structural benefits fully arrive. That is the gap investors are being asked to underwrite.
The Second-Order Question the Market Isn't Asking
The consensus read of this report is straightforward: higher prices plus rising volumes equal a recovering chemical cycle, and BASF — as the industry's bellwether — is proving it. The second-order question is different: what does BASF's pricing power tell us about the rest of the global chemical industry, and who is on the other side of these price increases?
When a European producer with structurally higher energy costs can raise prices 12 percent in a quarter and still grow volumes, it signals that global chemical capacity is tighter than the oversupply narrative suggests — at least in the specialties and intermediates where BASF competes. The beneficiaries extend beyond BASF: peers with similar exposure to price-recovery segments, from Covestro to specialty-chemical producers, are likely seeing the same pass-through dynamics. But the exposed parties are the downstream customers — automotive, construction, consumer goods — that are absorbing the cost increases and will eventually push back, either by substituting materials or by destocking.
There is also a currency dimension that cuts against the earnings quality. Part of the sales increase came from a weaker euro against the dollar and the renminbi, which inflates reported euro revenues without adding real volume or margin. When currency effects and cost pass-through are stripped out, the underlying demand signal is softer than the headline 14 percent sales growth implies.
The Counter-Thesis: Why This Rally Could Be Premature
The strongest argument against chasing BASF's guidance upgrades is that the company is being lifted by a temporary supply shock that is already rolling over. Fitch's expectation of a 2 percent EBITDA decline in 2027 rests on three pillars: a return to bottom-of-cycle margins as Middle East disruptions ease, persistent global chemical oversupply, and elevated European feedstock and energy costs that no amount of restructuring can fully neutralize.
There is also the matter of earnings quality. Reported EBIT of minus €98 million in the quarter — dragged down by the €318 million Monomers impairment and €1.3 billion in depreciation — is a reminder that BASF's asset-heavy European base still carries a heavy fixed-cost burden. The adjusted earnings per share of €0.72 looks healthy, but it excludes the very restructuring costs that define the company's current reality. Investors betting on a sustained recovery are effectively betting that the structural cost savings will arrive before the cyclical tailwinds fade.
The counter-thesis has a clear quantifiable trigger. If Brent crude and European energy prices stabilize or fall while chemical capacity additions in Asia and the Middle East come online as scheduled, BASF's price increases should prove unsustainable, and the 2027 earnings trajectory would validate Fitch's downgrade warning. Conversely, if BASF can hold its price increases through the first half of 2027 while volumes reaccelerate above 5 percent, the structural-turnaround thesis would be confirmed.
Market Positioning and What to Watch Next
BASF's shares closed at €52.04 in Frankfurt on Tuesday, October 27, roughly flat on the day, and were trading inside the upper half of their 52-week range of €41.48 to €55.05 ahead of the report. The stock has returned about 22 percent year to date, reflecting growing investor confidence in the restructuring story even before Wednesday's guidance raise.
For the near term, three signals will determine whether BASF's guidance path remains intact. First, volume trends in the Chemicals and Materials segments: a reacceleration above 5 percent would confirm genuine demand recovery; a stall below 2 percent would confirm the pass-through story. Second, the inventory line on the cash-flow statement: continued large inventory builds would signal that raw-material inflation is still working through the system, while a release of working capital would suggest the pass-through is complete. Third, the trajectory of European natural gas and naphtha prices, which set the floor for the company's cost structure.
Looking further out, the Zhanjiang Verbund site's ramp-up is the single biggest swing factor. If it reaches nameplate capacity on schedule and delivers its expected cost advantages, it would materially improve BASF's competitive position in Asia and offset European energy disadvantages. Delays or cost overruns there would leave the company exposed on both flanks — high European costs and missing Asian growth.
Scenarios for 2027 break down cleanly. In the base case, BASF holds most of its 2026 price increases, volumes grow modestly, and EBITDA before special items lands near the top of the current €7.4 billion to €7.8 billion range before flattening in 2027. In the upside case, the Middle East supply disruption persists longer than expected, Zhanjiang ramps ahead of schedule, and restructuring savings exceed targets — pushing EBITDA above €8 billion. In the downside case, the geopolitical premium evaporates, Asian capacity floods the market, and EBITDA falls back toward €6.5 billion, testing the credibility of management's restructuring narrative.
The bottom line: BASF's guidance raise is earned, but it is being earned on cyclical terms. The company is executing its structural transformation competently, yet the earnings that justify today's optimism are largely the product of a supply shock that will not last. Investors should treat the upgraded forecast as a confirmation of management's cost discipline, not as evidence that the chemical cycle has turned.
Explore more exclusive insights at nextfin.ai.
